Advanced search
Publication Cover
Expert Review of Respiratory Medicine Volume 10, 2016 - Issue 2
Submit an article Journal homepage
301
Views
10
CrossRef citations to date
0
Altmetric
Reviews

Tumor necrosis factor-α driven inflammation in alpha-1 antitrypsin deficiency: a new model of pathogenesis and treatment

Killian HurleyRespiratory Research Division, Department of Medicine, Royal College of Surgeons in Ireland Education and Research Centre, Beaumont Hospital, Dublin, IrelandCorrespondence[email protected]
,
Emer P. ReevesRespiratory Research Division, Department of Medicine, Royal College of Surgeons in Ireland Education and Research Centre, Beaumont Hospital, Dublin, Ireland
,
Tomás P. CarrollRespiratory Research Division, Department of Medicine, Royal College of Surgeons in Ireland Education and Research Centre, Beaumont Hospital, Dublin, Ireland
&
Noel G. McElvaneyRespiratory Research Division, Department of Medicine, Royal College of Surgeons in Ireland Education and Research Centre, Beaumont Hospital, Dublin, Ireland
Pages 207-222 | Received 13 Aug 2015, Accepted 01 Dec 2015, Published online: 18 Dec 2015

References

  • Papers of special note have been highlighted as:
  • • of interest
  • •• of considerable interest
  • De Serres FJ, Blanco I. Prevalence of alpha1-antitrypsin deficiency alleles PI*S and PI*Z worldwide and effective screening for each of the five phenotypic classes PI*MS, PI*MZ, PI*SS, PI*SZ, and PI*ZZ: a comprehensive review. Ther Adv Respir Dis. 2012;6(5):277–295.
  • Kelly E, Greene CM, Carroll TP, et al. Alpha-1 antitrypsin deficiency. Respir Med. 2010;104(6):763–772.
  • Brantly M, Nukiwa T, Crystal RG. Molecular basis of alpha-1-antitrypsin deficiency. Am J Med. 1988;84(6A):13–31.
  • American Thoracic S, European Respiratory S. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818–900.
  • Warter J, Storck D, Grosshans E, et al. [Weber-Christian syndrome associated with an alpha-1 antitrypsin deficiency. Familial investigation]. Ann Med Interne (Paris). 1972;123(10):877–882.
  • Barnett VT, Sekosan M, Khurshid A. Wegener’s granulomatosis and alpha1-antitrypsin-deficiency emphysema: proteinase-related diseases. Chest. 1999;116(1):253–255.
  • Fregonese L, Stolk J, Frants RR, et al. Alpha-1 antitrypsin null mutations and severity of emphysema. Respir Med. 2008;102(6):876–884.
  • Carroll TP, O’Connor CA, Floyd O, et al. The prevalence of alpha-1 antitrypsin deficiency in Ireland. Respir Res. 2011;12:91.
  • Hersh CP, Dahl M, Ly NP, et al. Chronic obstructive pulmonary disease in alpha1-antitrypsin PI MZ heterozygotes: a meta-analysis. Thorax. 2004;59(10):843–849.
  • Molloy K, Hersh CP, Morris VB, et al. Clarification of the risk of chronic obstructive pulmonary disease in alpha1-antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med. 2014;189(4):419–427.
  • Malerba M, Ricciardolo F, Radaeli A, et al. Neutrophilic inflammation and IL-8 levels in induced sputum of alpha-1-antitrypsin PiMZ subjects. Thorax. 2006;61(2):129–133.
  • Bergin DA, Hurley K, McElvaney NG, et al. Alpha-1 antitrypsin: a potent anti-inflammatory and potential novel therapeutic agent. Arch Immunol Ther Exp (Warsz). 2012;60(2):81–97.
  • Bergin DA, Reeves EP, Meleady P, et al. alpha-1 antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J Clin Invest. 2010;120(12):4236–4250.
  • O’Dwyer CA, O’Brien ME, Wormald MR, et al. The BLT1 inhibitory function of alpha-1 antitrypsin augmentation therapy disrupts leukotriene B4 neutrophil signaling. J Immunol. 2015;195(8):3628–3641.
  • Nita IM, Serapinas D, Janciauskiene SM. Alpha1-antitrypsin regulates CD14 expression and soluble CD14 levels in human monocytes in vitro. Int J Biochem Cell Biol. 2007;39(6):1165–1176.
  • Bergin DA, Reeves EP, Hurley K, et al. The circulating proteinase inhibitor alpha-1 antitrypsin regulates neutrophil degranulation and autoimmunity. Sci Transl Med. 2014;6(217):217ra211.
  • Janciauskiene S, Larsson S, Larsson P, et al. Inhibition of lipopolysaccharide-mediated human monocyte activation, in vitro, by alpha1-antitrypsin. Biochem Biophys Res Commun. 2004;321(3):592–600.
  • Bucurenci N, Blake DR, Chidwick K, et al. Inhibition of neutrophil superoxide production by human plasma alpha 1-antitrypsin. FEBS Lett. 1992;300(1):21–24.
  • Guttman O, Baranovski BM, Schuster R, et al. Acute-phase protein alpha1-anti-trypsin: diverting injurious innate and adaptive immune responses from non-authentic threats. Clin Exp Immunol. 2015;179(2):161–172.
  • Mizrahi M, Cal P, Rosenthal M, et al. Human alpha1-antitrypsin modifies B-lymphocyte responses during allograft transplantation. Immunology. 2013;140(3):362–373.
  • Ozeri E, Mizrahi M, Shahaf G, et al. Alpha-1 antitrypsin promotes semimature, IL-10-producing and readily migrating tolerogenic dendritic cells. J Immunol. 2012;189(1):146–153.
  • Lewis EC, Mizrahi M, Toledano M, et al. Alpha1-antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice. Proc Natl Acad Sci U S A. 2008;105(42):16236–16241.
  • Shahaf G, Moser H, Ozeri E, et al. Alpha-1-antitrypsin gene delivery reduces inflammation, increases T-regulatory cell population size and prevents islet allograft rejection. Mol Med. 2011;17(9–10):1000–1011.
  • Subramanian S, Shahaf G, Ozeri E, et al. Sustained expression of circulating human alpha-1 antitrypsin reduces inflammation, increases CD4+FoxP3+ Treg cell population and prevents signs of experimental autoimmune encephalomyelitis in mice. Metabolic Brain Disease. 2011;26(2):107–113.
  • Petrache I, Fijalkowska I, Zhen L, et al. A novel antiapoptotic role for alpha1-antitrypsin in the prevention of pulmonary emphysema. Am J Respir Crit Care Med. 2006;173(11):1222–1228.
  • Kalis M, Kumar R, Janciauskiene S, et al. Alpha 1-antitrypsin enhances insulin secretion and prevents cytokine-mediated apoptosis in pancreatic beta-cells. Islets. 2010;2(3):185–189.
  • Petrache I, Fijalkowska I, Medler TR, et al. Alpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis. Am J Pathol. 2006;169(4):1155–1166.
  • Heresi GA, Stoller JK. Augmentation therapy in alpha-1 antitrypsin deficiency. Expert Opin Biol Ther. 2008;8(4):515–526.
  • Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med. 1987;316(17):1055–1062.

•• The documentation of replacement therapy with AAT as a logical approach to long-term medical treatment in patients with AATD

  • Wencker M, Fuhrmann B, Banik N, et al. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest. 2001;119(3):737–744.
  • Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest. 2000;118(5):1480–1485.
  • Di Francia M, Barbier D, Mege JL, et al. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1994;150(5 Pt 1):1453–1455.
  • Takabatake N, Nakamura H, Abe S, et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161(4 Pt 1):1179–1184.
  • Salamone G, Giordano M, Trevani AS, et al. Promotion of neutrophil apoptosis by TNF-alpha. J Immunol. 2001;166(5):3476–3483.
  • Cross A, Moots RJ, Edwards SW. The dual effects of TNFalpha on neutrophil apoptosis are mediated via differential effects on expression of Mcl-1 and Bfl-1. Blood. 2008;111(2):878–884.
  • Wright HL, Chikura B, Bucknall RC, et al. Changes in expression of membrane TNF, NF-{kappa}B activation and neutrophil apoptosis during active and resolved inflammation. Ann Rheum Dis. 2011;70(3):537–543.
  • van den Berg JM, Weyer S, Weening JJ, et al. Divergent effects of tumor necrosis factor alpha on apoptosis of human neutrophils. J Leukoc Biol. 2001;69(3):467–473.
  • Sack M. Tumor necrosis factor-alpha in cardiovascular biology and the potential role for anti-tumor necrosis factor-alpha therapy in heart disease. Pharmacology & Therapeutics. 2002;94(1–2):123–135.
  • Sarzi-Puttini P, Atzeni F, Shoenfeld Y, et al. TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmunity Reviews. 2005;4(3):153–161.
  • Mukhopadhyay S, Hoidal JR, Mukherjee TK. Role of TNFalpha in pulmonary pathophysiology. Respir Res. 2006;7:125.
  • Geering B, Gurzeler U, Federzoni E, et al. A novel TNFR1-triggered apoptosis pathway mediated by class IA PI3Ks in neutrophils. Blood. 2011;117(22):5953–5962.
  • Kips JC, Tavernier JH, Joos GF, et al. The potential role of tumour necrosis factor alpha in asthma. Clin Exp Allergy. 1993;23(4):247–250.
  • Gosset P, Tsicopoulos A, Wallaert B, et al. Increased secretion of tumor necrosis factor alpha and interleukin-6 by alveolar macrophages consecutive to the development of the late asthmatic reaction. J Allergy Clin Immun. 1991;88(4):561–571.
  • Cembrzynska-Nowak M, Szklarz E, Inglot AD, et al. Elevated release of tumor necrosis factor-alpha and interferon-gamma by bronchoalveolar leukocytes from patients with bronchial asthma. Am Rev Respir Dis. 1993;147(2):291–295.
  • Obase Y, Shimoda T, Mitsuta K, et al. Correlation between airway hyperresponsiveness and airway inflammation in a young adult population: eosinophil, ECP, and cytokine levels in induced sputum. Ann Allerg Asthma Im. 2001;86(3):304–310.
  • Harkonen E, Virtanen I, Linnala A, et al. Modulation of fibronectin and tenascin production in human bronchial epithelial cells by inflammatory cytokines in vitro. Am J Respir Cell Mol Biol. 1995;13(1):109–115.
  • Lilly CM, Nakamura H, Kesselman H, et al. Expression of eotaxin by human lung epithelial cells: induction by cytokines and inhibition by glucocorticoids. J Clin Invest. 1997;99(7):1767–1773.
  • Smart SJ, Casale TB. Pulmonary epithelial cells facilitate TNF-alpha-induced neutrophil chemotaxis. A role for cytokine networking. J Immunol. 1994;152(8):4087–4094.
  • Godding V, Stark JM, Sedgwick JB, et al. Adhesion of activated eosinophils to respiratory epithelial cells is enhanced by tumor necrosis factor-alpha and interleukin-1 beta. Am J Respir Cell Mol Biol. 1995;13(5):555–562.
  • Smart SJ, Casale TB. TNF-alpha-induced transendothelial neutrophil migration is IL-8 dependent. Am J Physiol. 1994;266(3 Pt 1):L238–245.
  • Churg A, Wang RD, Tai H, et al. Tumor necrosis factor-alpha drives 70% of cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med. 2004;170(5):492–498.
  • Chung KF. Cytokines in chronic obstructive pulmonary disease. Eur Respir J Supl. 2001;34:50s–59s.
  • Sulkowska M, Sulkowski S, Terlikowski S, et al. Tumor necrosis factor-alpha induces emphysema-like pulmonary tissue rebuilding. Changes in type II alveolar epithelial cells. Pol J Pathol. 1997;48(3):179–188.
  • Fujita M, Shannon JM, Irvin CG, et al. Overexpression of tumor necrosis factor-alpha produces an increase in lung volumes and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2001;280(1):L39–49.
  • Lundblad LK, Thompson-Figueroa J, Leclair T, et al. Tumor necrosis factor-alpha overexpression in lung disease: a single cause behind a complex phenotype. Am J Respir Crit Care Med. 2005;171(12):1363–1370.
  • Vuillemenot BR, Rodriguez JF, Hoyle GW. Lymphoid tissue and emphysema in the lungs of transgenic mice inducibly expressing tumor necrosis factor-alpha. Am J Respir Cell Mol Biol. 2004;30(4):438–448.
  • Rahman I, Gilmour PS, Jimenez LA, et al. Oxidative stress and TNF-alpha induce histone acetylation and NF-kappaB/AP-1 activation in alveolar epithelial cells: potential mechanism in gene transcription in lung inflammation. Mol Cell Biochem. 2002;234–235(1–2):239–248.
  • Mackay F, Loetscher H, Stueber D, et al. Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J Exp Med. 1993;177(5):1277–1286.
  • Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996;153(2):530–534.
  • Mueller R, Chanez P, Campbell AM, et al. Different cytokine patterns in bronchial biopsies in asthma and chronic bronchitis. Resp Med. 1996;90(2):79–85.
  • Daldegan MB, Teixeira MM, Talvani A. Concentration of CCL11, CXCL8 and TNF-alpha in sputum and plasma of patients undergoing asthma or chronic obstructive pulmonary disease exacerbation. Braz J Med Biol Res. 2005;38(9):1359–1365.
  • Hacievliyagil SS, Gunen H, Mutlu LC, et al. Association between cytokines in induced sputum and severity of chronic obstructive pulmonary disease. Resp Med. 2006;100(5):846–854.
  • de Godoy I, Donahoe M, Calhoun WJ, et al. Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med. 1996;153(2):633–637.
  • Sun G, Stacey MA, Vittori E, et al. Cellular and molecular characteristics of inflammation in chronic bronchitis. Eur J Clin Invest. 1998;28(5):364–372.
  • Aaron SD, Angel JB, Lunau M, et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163(2):349–355.
  • Sakao S, Tatsumi K, Igari H, et al. Association of tumor necrosis factor alpha gene promoter polymorphism with the presence of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163(2):420–422.
  • Sakao S, Tatsumi K, Igari H, et al. Association of tumor necrosis factor-alpha gene promoter polymorphism with low attenuation areas on high-resolution CT in patients with COPD. Chest. 2002;122(2):416–420.
  • Keatings VM, Cave SJ, Henry MJ, et al. A polymorphism in the tumor necrosis factor-alpha gene promoter region may predispose to a poor prognosis in COPD. Chest. 2000;118(4):971–975.
  • Hersh CP, Demeo DL, Lange C, et al. Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations. Am J Respir Cell Mol Biol. 2005;33(1):71–78.
  • Churg A, Wang X, Wang RD, et al. Alpha1-antitrypsin suppresses TNF-alpha and MMP-12 production by cigarette smoke-stimulated macrophages. Am J Respir Cell Mol Biol. 2007;37(2):144–151.

• Demonstrates that TNF-α release by alveolar macrophages is modulated by AAT

  • Subramaniyam D, Virtala R, Pawlowski K, et al. TNF-alpha-induced self expression in human lung endothelial cells is inhibited by native and oxidized alpha1-antitrypsin. Int J Biochem Cell Biol. 2008;40(2):258–271.
  • Churg A, Wang RD, Tai H, et al. Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-alpha release. Am J Respir Crit Care Med. 2003;167(8):1083–1089.

•• Demonstrates that mice exposed to cigarette smoke and treated with exogenous AAT were protected against the development of emphysema and increased levels of serum TNF-α

  • Hurley K, Lacey N, O’Dwyer CA, et al. Alpha-1 antitrypsin augmentation therapy corrects accelerated neutrophil apoptosis in deficient individuals. J Immunol. 2014;193(8):3978–3991.

•• The identification of misfolded Z-AAT protein within the ER of neutrophils leading to the release of TNF-α

  • Geraghty P, Eden E, Pillai M, et al. Alpha1-antitrypsin activates protein phosphatase 2A to counter lung inflammatory responses. Am J Respir Crit Care Med. 2014;190(11):1229–1242.

• AAT modulates protein phosphatase 2A to modulate inflammatory induced by TNF signaling in the lung

  • Stockley RA, Shaw J, Afford SC, et al. Effect of alpha-1-proteinase inhibitor on neutrophil chemotaxis. Am J Respir Cell Mol Biol. 1990;2(2):163–170.
  • Lockett AD, Kimani S, Ddungu G, et al. Alpha(1)-antitrypsin modulates lung endothelial cell inflammatory responses to TNF-alpha. Am J Respir Cell Mol Biol. 2013;49(1):143–150.
  • Jonigk D, Al-Omari M, Maegel L, et al. Anti-inflammatory and immunomodulatory properties of alpha1-antitrypsin without inhibition of elastase. Proc Natl Acad Sci U S A. 2013;110(37):15007–15012.
  • Wood AM, Simmonds MJ, Bayley DL, et al. The TNFalpha gene relates to clinical phenotype in alpha-1-antitrypsin deficiency. Respir Res. 2008;9:52.
  • Griese M, Latzin P, Kappler M, et al. alpha1-antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J. 2007;29(2):240–250.

•• Documentation of the ability of inhaled AAT to decreased the levels of elastase activity, neutrophils and pro-inflammatory cytokines in airways of patients with CF

  • Nita I, Hollander C, Westin U, et al. Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release. Respir Res. 2005;6:12.
  • Janciauskiene SM, Nita IM, Stevens T. Alpha1-antitrypsin, old dog, new tricks. Alpha1-antitrypsin exerts in vitro anti-inflammatory activity in human monocytes by elevating cAMP. J Biol Chem. 2007;282(12):8573–8582.
  • Jie Z, Cai Y, Yang W, et al. Protective effects of alpha 1-antitrypsin on acute lung injury in rabbits induced by endotoxin. Chin Med J (Engl). 2003;116(11):1678–1682.
  • Zhang B, Lu Y, Campbell-Thompson M, et al. Alpha1-antitrypsin protects beta-cells from apoptosis. Diabetes. 2007;56(5):1316–1323.
  • Lewis EC, Shapiro L, Bowers OJ, et al. Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice. Proc Natl Acad Sci U S A. 2005;102(34):12153–12158.
  • Van Molle W, Libert C, Fiers W, et al. Alpha 1-acid glycoprotein and alpha 1-antitrypsin inhibit TNF-induced but not anti-Fas-induced apoptosis of hepatocytes in mice. J Immunol. 1997;159(7):3555–3564.
  • Aggarwal BB, Graff K, Samal B, et al. Regulation of two forms of the TNF receptors by phorbol ester and dibutyryl cyclic adenosine 3’,5’-monophosphate in human histiocytic lymphoma cell line U-937. Lymphokine Cytok Res. 1993;12(3):149–158.
  • MacEwan DJ. TNF receptor subtype signalling: differences and cellular consequences. Cell Signal. 2002;14(6):477–492.
  • Gearing AJ, Beckett P, Christodoulou M, et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature. 1994;370(6490):555–557.
  • Smookler DS, Mohammed FF, Kassiri Z, et al. Tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation. J Immunol. 2006;176(2):721–725.
  • Horiuchi T, Mitoma H, Harashima S, et al. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology. 2010;49(7):1215–1228.
  • Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997;385(6618):729–733.
  • Solomon KA, Pesti N, Wu G, et al. Cutting edge: a dominant negative form of TNF-alpha converting enzyme inhibits proTNF and TNFRII secretion. J Immunol. 1999;163(8):4105–4108.
  • Reddy P, Slack JL, Davis R, et al. Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem. 2000;275(19):14608–14614.
  • Matthews V, Schuster B, Schutze S, et al. Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem. 2003;278(40):38829–38839.
  • Walcheck B, Herrera AH, St Hill C, et al. ADAM17 activity during human neutrophil activation and apoptosis. Eur J Immunol. 2006;36(4):968–976.
  • Chalaris A, Rabe B, Paliga K, et al. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood. 2007;110(6):1748–1755.
  • Wang Y, Zhang AC, Ni Z, et al. ADAM17 activity and other mechanisms of soluble L-selectin production during death receptor-induced leukocyte apoptosis. J Immunol. 2010;184(8):4447–4454.
  • Aderka D, Engelmann H, Maor Y, et al. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 1992;175(2):323–329.
  • Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science. 2002;296(5573):1634–1635.
  • Muppidi JR, Tschopp J, Siegel RM. Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity. 2004;21(4):461–465.
  • Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 2003;114(2):181–190.
  • Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell. 2008;133(4):693–703.
  • Kim EY, Teh HS. Critical role of TNF receptor type-2 (p75) as a costimulator for IL-2 induction and T cell survival: a functional link to CD28. J Immunol. 2004;173(7):4500–4509.
  • Zhao X, Mohaupt M, Jiang J, et al. Tumor necrosis factor receptor 2-mediated tumor suppression is nitric oxide dependent and involves angiostasis. Cancer Res. 2007;67(9):4443–4450.
  • Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med. 2000;343(4):269–280.
  • Hubbard RC, Fells G, Gadek J, et al. Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages. J Clin Invest. 1991;88(3):891–897.
  • Rouhani F, Paone G, Smith NK, et al. Lung neutrophil burden correlates with increased pro-inflammatory cytokines and decreased lung function in individuals with alpha(1)-antitrypsin deficiency. Chest. 2000;117(5 Suppl 1):250S–251S.
  • Spencer LT, Paone G, Krein PM, et al. Role of human neutrophil peptides in lung inflammation associated with alpha1-antitrypsin deficiency. Am J Physiol Lung Cell Mol Physiol. 2004;286(3):L514–520.
  • Kennedy AD, DeLeo FR. Neutrophil apoptosis and the resolution of infection. Immunol Res. 2009;43(1–3):25–61.
  • Courtney PA, Crockard AD, Williamson K, et al. Increased apoptotic peripheral blood neutrophils in systemic lupus erythematosus: relations with disease activity, antibodies to double stranded DNA, and neutropenia. Ann Rheum Dis. 1999;58(5):309–314.
  • Spriggs DR, Sherman ML, Imamura K, et al. Phospholipase A2 activation and autoinduction of tumor necrosis factor gene expression by tumor necrosis factor. Cancer Res. 1990;50(22):7101–7107.
  • Sato M, Miyazaki T, Nagaya T, et al. Antioxidants inhibit tumor necrosis factor-alpha mediated stimulation of interleukin-8, monocyte chemoattractant protein-1, and collagenase expression in cultured human synovial cells. J Rheumatol. 1996;23(3):432–438.
  • Fiedler MA, Wernke-Dollries K, Stark JM. Inhibition of TNF-alpha-induced NF-kappaB activation and IL-8 release in A549 cells with the proteasome inhibitor MG-132. Am J Respir Cell Mol Biol. 1998;19(2):259–268.
  • Brandt E, Petersen F, Flad HD. Recombinant tumor necrosis factor-alpha potentiates neutrophil degranulation in response to host defense cytokines neutrophil-activating peptide 2 and IL-8 by modulating intracellular cyclic AMP levels. J Immunol. 1992;149(4):1356–1364.
  • Chikazawa H, Nishiya K, Matsumori A, et al. Immunoglobulin isotypes of anti-myeloperoxidase and anti-lactoferrin antibodies in patients with collagen diseases. J Clin Immunol. 2000;20(4):279–286.
  • Locht H, Skogh T, Kihlstrom E. Anti-lactoferrin antibodies and other types of anti-neutrophil cytoplasmic antibodies (ANCA) in reactive arthritis and ankylosing spondylitis. Clin Exp Immunol. 1999;117(3):568–573.
  • Roozendaal C, Horst G, Pogany K, et al. Prevalence and clinical significance of anti-lactoferrin autoantibodies in inflammatory bowel diseases and primary sclerosing cholangitis. Adv Exp Med Biol. 1998;443:313–319.
  • Caccavo D, Rigon A, Picardi A, et al. Anti-lactoferrin antibodies in systemic lupus erythematosus: isotypes and clinical correlates. Clin Rheumatol. 2005;24(4):381–387.
  • Mocsai A, Jakus Z, Vantus T, et al. Kinase pathways in chemoattractant-induced degranulation of neutrophils: the role of p38 mitogen-activated protein kinase activated by Src family kinases. J Immunol. 2000;164(8):4321–4331.
  • Graziadei I, Kaserbacher R, Braunsteiner H, et al. The hepatic acute-phase proteins alpha 1-antitrypsin and alpha 2-macroglobulin inhibit binding of transferrin to its receptor. Biochem J. 1993;290(Pt 1):109–113.
  • Knoell DL, Ralston DR, Coulter KR, et al. Alpha 1-antitrypsin and protease complexation is induced by lipopolysaccharide, interleukin-1beta, and tumor necrosis factor-alpha in monocytes. Am J Respir Crit Care Med. 1998;157(1):246–255.
  • Bourne HR, Lichtenstein LM, Melmon KL, et al. Modulation of inflammation and immunity by cyclic AMP. Science. 1974;184(132):19–28.
  • Grau GE, Mili N, Lou JN, et al. Phenotypic and functional analysis of pulmonary microvascular endothelial cells from patients with acute respiratory distress syndrome. Lab Invest. 1996;74(4):761–770.
  • Elzouki AN, Segelmark M, Wieslander J, et al. Strong link between the alpha 1-antitrypsin PiZ allele and Wegener’s granulomatosis. J Intern Med. 1994;236(5):543–548.
  • Lockett AD, Van Demark M, Gu Y, et al. Effect of cigarette smoke exposure and structural modifications on the alpha-1 antitrypsin interaction with caspases. Mol Med. 2012;18:445–454.
  • Aldonyte R, Hutchinson TE, Jin B, et al. Endothelial alpha-1-antitrypsin attenuates cigarette smoke induced apoptosis in vitro. Copd. 2008;5(3):153–162.
  • Sohrab S, Petrusca DN, Lockett AD, et al. Mechanism of alpha-1 antitrypsin endocytosis by lung endothelium. Faseb J. 2009;23(9):3149–3158.
  • Stocks JM, Brantly M, Pollock D, et al. Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha1-proteinase inhibitor, zemaira. Copd. 2006;3(1):17–23.
  • Martin SL, Downey D, Bilton D, et al. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol. 2006;41(2):177–183.
  • Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The alpha-1-antitrypsin deficiency registry study group. Am J Respir Crit Care Med. 1998;158(1):49–59.
  • Chapman KR, Burdon JG, Piitulainen E, et al. Intravenous augmentation treatment and lung density in severe alpha1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9991):360–368.

•• Evidence that purified AAT augmentation slows progression of emphysema

  • Russi EW. Alpha-1 antitrypsin: now available, but do we need it? Swiss Med Wkly. 2008;138(13–14):191–196.
  • Schmid ST, Koepke J, Dresel M, et al. The effects of weekly augmentation therapy in patients with PiZZ alpha1-antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis. 2012;7:687–696.
  • Stockley RA, Bayley DL, Unsal I, et al. The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2002;165(11):1494–1498.
  • van Riemsdijk-van Overbeeke IC, Baan CC, Hesse CJ, et al. TNF-alpha: mRNA, plasma protein levels and soluble receptors in patients on chronic hemodialysis, on CAPD and with end-stage renal failure. Clin Nephrol. 2000;53(2):115–123.
  • Takabatake N, Nakamura H, Inoue S, et al. Circulating levels of soluble Fas ligand and soluble Fas in patients with chronic obstructive pulmonary disease. Respir Med. 2000;94(12):1215–1220.
  • Eagan TM, Ueland T, Wagner PD, et al. Systemic inflammatory markers in COPD: results from the Bergen COPD cohort study. Eur Respir J. 2010;35(3):540–548.
  • Hull J, Thomson AH. Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis. Thorax. 1998;53(12):1018–1021.
  • Karpati F, Hjelte FL, Wretlind B. TNF-alpha and IL-8 in consecutive sputum samples from cystic fibrosis patients during antibiotic treatment. Scand J Infect Dis. 2000;32(1):75–79.
  • McElvaney NG, Hubbard RC, Birrer P, et al. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet. 1991;337(8738):392–394.
  • Brand P, Schulte M, Wencker M, et al. Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency. Eur Respir J. 2009;34(2):354–360.
  • Geller DE, Kesser KC. The I-neb adaptive aerosol delivery system enhances delivery of alpha1-antitrypsin with controlled inhalation. J Aerosol Med Pulm Drug Deliv. 2010;23(Suppl 1):S55–59.
  • Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 2007;29(6):1224–1238.
  • Qiu Y, Zhu J, Bandi V, et al. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;168(8):968–975.
  • White AJ, Gompertz S, Stockley RA. Chronic obstructive pulmonary disease. 6: the aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax. 2003;58(1):73–80.
  • Suissa S, Ernst P, Hudson M. TNF-alpha antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2008;21(1):234–238.
  • Kawai S, Sekino H, Yamashita N, et al. The comparability of etanercept pharmacokinetics in healthy Japanese and American subjects. J Clin Pharmacol. 2006;46(4):418–423.
  • Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(9):926–934.
  • Aaron SD, Vandemheen KL, Maltais F, et al. TNFalpha antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial. Thorax. 2013;68(2):142–148.
  • Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2012;186(1):48–55.
  • Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662–671.
  • Forssmann WG, Yh T, Stoll M, et al. Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide. Sci Transl Med. 2010;2(63):63re63.
  • Munch J, Standker L, Adermann K, et al. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell. 2007;129(2):263–275.
  • Shapiro L, Pott GB, Ralston AH. Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1. Faseb J. 2001;15(1):115–122.
  • Blanco I, Lara B, de Serres F. Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema. Orphanet J Rare Dis. 2011;6(4):14–25.
  • Al-Niaimi F, Lyon C. Severe ulcerative panniculitis caused by alpha 1-antitrypsin deficiency: remission induced and maintained with intravenous alpha 1-antitrypsin. J Am Acad Dermatol. 2011;65(1):227–229.
  • Collins CB, Aherne CM, Ehrentraut SF, et al. Alpha-1-antitrypsin therapy ameliorates acute colitis and chronic murine ileitis. Inflamm Bowel Dis. 2013;19(9):1964–1973.
  • Grimstein C, Choi YK, Satoh M, et al. Combination of alpha-1 antitrypsin and doxycycline suppresses collagen-induced arthritis. J Gene Med. 2010;12(1):35–44.
  • Grimstein C, Choi YK, Wasserfall CH, et al. Alpha-1 antitrypsin protein and gene therapies decrease autoimmunity and delay arthritis development in mouse model. J Transl Med. 2010;9:21.
  • Tawara I, Sun Y, Lewis EC, et al. Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Proc Natl Acad Sci U S A. 2012;109(2):564–569.
  • Abecassis A, Schuster R, Shahaf G, et al. alpha1-antitrypsin increases interleukin-1 receptor antagonist production during pancreatic islet graft transplantation. Cell Mol Immunol. 2014;11(4):377–386.
  • Bellacen K, Kalay N, Ozeri E, et al. Revascularization of pancreatic islet allografts is enhanced by alpha-1-antitrypsin under anti-inflammatory conditions. Cell Transplant. 2013;22(11):2119–2133.
  • Rachmiel M, Strauss P, Dror N, et al. Alpha-1 antitrypsin therapy is safe and well tolerated in children and adolescents with recent onset type 1 diabetes mellitus. Pediatr Diabetes. 2015. doi: 10.1111/pedi.12283. [Epub ahead of print].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.